Guardant Health (NASDAQ:GH) Price Target Lowered to $35.00 at Sanford C. Bernstein

Guardant Health (NASDAQ:GH) had its target price decreased by Sanford C. Bernstein from $40.00 to $35.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Sanford C. Bernstein’s price objective suggests a potential upside of 49.51% from the company’s current price.

GH has been the topic of a number of other reports. Piper Sandler upped their target price on shares of Guardant Health from $30.00 to $34.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. Leerink Partners dropped their target price on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. JPMorgan Chase & Co. upped their target price on shares of Guardant Health from $45.00 to $48.00 and gave the stock an “overweight” rating in a research note on Thursday, August 8th. Bank of America upped their price target on shares of Guardant Health from $28.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, July 18th. Finally, The Goldman Sachs Group upped their price target on shares of Guardant Health from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, July 17th. One equities research analyst has rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $40.00.

Guardant Health Trading Up 7.4 %

NASDAQ:GH traded up $1.62 during mid-day trading on Wednesday, hitting $23.41. 1,074,815 shares of the stock traded hands, compared to its average volume of 2,037,503. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of -5.97 and a beta of 1.11. Guardant Health has a 52 week low of $15.81 and a 52 week high of $37.04. The firm’s 50 day moving average is $23.49 and its two-hundred day moving average is $25.66. The company has a quick ratio of 6.07, a current ratio of 6.40 and a debt-to-equity ratio of 16.70.

Guardant Health (NASDAQ:GH) last issued its earnings results on Wednesday, August 7th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.10). The company had revenue of $177.24 million during the quarter, compared to the consensus estimate of $162.59 million. Guardant Health had a negative return on equity of 418.21% and a negative net margin of 76.23%. Guardant Health’s revenue was up 29.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.67) earnings per share. On average, equities research analysts predict that Guardant Health will post -3.31 earnings per share for the current year.

Institutional Trading of Guardant Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in Guardant Health during the second quarter valued at $44,000. Canton Hathaway LLC acquired a new stake in Guardant Health during the second quarter valued at $59,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Guardant Health during the second quarter valued at $71,000. Byrne Asset Management LLC acquired a new stake in Guardant Health during the second quarter valued at $77,000. Finally, Manchester Capital Management LLC acquired a new stake in Guardant Health during the first quarter valued at $57,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.